These results demonstrate that UHRF1 plays a critical role in KRAS-driven tumorigenesis and may be an attractive drug target for the treatment of KRAS mutant NSCLC and/or other KRAS-driven cancers. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.